Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
The present invention relates to a stable liquid preparation comprising a camptothecin derivative which is prepared by binding a compound of the formula [I]: wherein R 1 is a substituted or unsubstituted lower alkyl group, X 1 is a group of the formula: —NHR 2 (R 2 is a hydrogen atom or a lower alkyl group) or a hydroxy group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable sat thereof, which is adjusted to pH 5-8, or a stable pharmaceutical composition produced by lyophilizing said liquid preparation.
1 . A liquid preparation comprising a camptothecin derivative which is prepared by binding a compound of the formula [I]:
wherein R 1 is a substituted or unsubstituted lower alkyl group, X 1 is a group of the formula: —NHR 2 (R 2 is a hydrogen atom or a lower alkyl group) or a hydroxy group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof, which is adjusted to pH 5-8.
2 . The liquid preparation according to claim 1 wherein one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogen phosphate are used as the buffer.
3 . The liquid preparation according to claim 2 wherein ionic strength of the buffer is 0.2 or less than 0.2.
4 . The liquid preparation according to any one of claims 1 to 3 wherein the pH is adjusted to 5 to 7.5.
5 . The liquid preparation according to any one of claims 1 to 3 wherein the pH is adjusted to 5 to 7.
6 . The liquid preparation according to any of claims 1 to 3 wherein the pH is adjusted to 6 to 7.
7 . The liquid preparation according to any one of claims 1 to 6 wherein the amount of the camptothecin derivative or its pharmaceutically acceptable salt is 1% to 20%.
8 . The liquid preparation according to claim 1 , wherein one ore more ingredients selected from a stabilizer and a filler are further contained.
9 . The liquid preparation according to claim 1 , wherein one or more stabilizers selected from an alkali metal carbonate and alkali metal hydrogen carbonate, and one ore more fillers selected from lactose, sucrose, mannitol, dextran, maltose and trehalose are further contained.
10 . The liquid preparation according to claim 1 , wherein one or more salts selected from an alkali metal chloride, an alkaline earth metal chloride and an alkali metal sulphate are further contained.
11 . The liquid preparation according to claim 1 wherein R 1 is an unsubstituted C 1-6 alkyl group, X 1 is an amino group and Alk is a straight chain C 1-6 alkylene group not interrupted by an oxygen atom, a polysaccharide is a carboxymethylated dextran or pullulan, and a peptide is a peptide consisting of 2-5 amino acids.
12 . The liquid preparation according to claim 11 wherein R 1 is ethyl group, a group of the formula: X 1 -Alk-O— is 3-aminopropyloxy group, and the camptothecin compound [I] is bound at position 10 of a camptothecin nucleus, the polysaccharide is dextran in which a carboxyl group is introduced, the peptide is glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine (SEQ ID NO: 1), glycyl-glycyl-glycyl-glycyl-glycine (SEQ ID NO: 2), L- or D-phenylalanyl-glycine, and L- or D-leucyl-glycine.
13 . The liquid preparation according to claim 12 wherein the peptide is glycyl-glycyl-glycine.
14 . A lyophilized drug composition prepared by lyophilizing the liquid preparation according to claim 1 .
15 . A liquid composition for injection wherein the composition according to claim 14 is dissolved in an aqueous medium.
16 . A liquid preparation comprising a camptothesin derivative, which is prepared by binding a compound of the formula (Ia):
and a dextran having carboxylic groups via glycil-glycil-glycil, or a pharmaceutically acceptable salt thereof, wherein the liquid preparation is adjusted to pH 5 to 8 with a buffer.
17 . The liquid preparation according to claim 16 , wherein the buffer is one or more compounds selected from the ciric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogen phosphate.
18 . The liquid preparation according to claim 17 , wherein the buffer is citric acid and sodium dihydrogen phosphate.
19 . The liquid preparation according to claim 18 , wherein sodium chloride is further contained.